These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 9528002)

  • 1. Pharmacogenomics: will the regulators approve?
    Hodgson J; Marshall A
    Nat Biotechnol; 1998 Mar; 16(3):243-6. PubMed ID: 9528002
    [No Abstract]   [Full Text] [Related]  

  • 2. Cautious welcome for FDA pharmacogenomics guidance.
    Katsnelson A;
    Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
    [No Abstract]   [Full Text] [Related]  

  • 3. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
    Binzak BA
    Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacogenomics. Going from genome to pill.
    Service RF
    Science; 2005 Jun; 308(5730):1858-60. PubMed ID: 15976283
    [No Abstract]   [Full Text] [Related]  

  • 5. The problem of new uses.
    Eisenberg RS
    Yale J Health Policy Law Ethics; 2005; 5(2):717-39. PubMed ID: 16052897
    [No Abstract]   [Full Text] [Related]  

  • 6. Trouble at the office.
    Allison M
    Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
    [No Abstract]   [Full Text] [Related]  

  • 7. Biotech industry struggles with generics approval.
    Knight J
    Nature; 2004 Jun; 429(6992):588. PubMed ID: 15190316
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pharmacogenetic-assisted drug development. Regulatory aspects from the viewpoint of the Medical Products Agency].
    Theilade MD
    Ugeskr Laeger; 2005 May; 167(20):2146-50. PubMed ID: 15987069
    [No Abstract]   [Full Text] [Related]  

  • 9. Investing in risk management.
    Fiscus PW
    Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
    [No Abstract]   [Full Text] [Related]  

  • 10. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective.
    Lesko LJ; Woodcock J
    Nat Rev Drug Discov; 2004 Sep; 3(9):763-9. PubMed ID: 15340386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with voluntary and required genomic data submissions to the FDA: summary report from track 1 of the third FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop.
    Frueh FW; Rudman A; Simon K; Gutman S; Reed C; Dorner AJ
    Pharmacogenomics J; 2006; 6(5):296-300. PubMed ID: 16568150
    [No Abstract]   [Full Text] [Related]  

  • 12. External influences on protocol design.
    Spilker B
    Epilepsy Res Suppl; 1993; 10():115-24. PubMed ID: 8251087
    [No Abstract]   [Full Text] [Related]  

  • 13. What will it take to reap the clinical benefits of pharmacogenomics?
    Evans BJ
    Food Drug Law J; 2006; 61(4):753-94. PubMed ID: 17180771
    [No Abstract]   [Full Text] [Related]  

  • 14. The needs of the few.
    Nature; 2010 Jul; 466(7303):160. PubMed ID: 20613796
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulatory agency consideration of pharmacogenomics.
    Pendergast MK
    Exp Biol Med (Maywood); 2008 Dec; 233(12):1498-503. PubMed ID: 18849547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development.
    Milton MN; Horvath CJ
    Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571
    [No Abstract]   [Full Text] [Related]  

  • 17. Patients, physicians, and clinical trials: the other side of the coins.
    Abramson SB; Flexner C; Snyderman R; Dieterich DT; Korn D; Temple R; Sherwood L; Goldblatt D
    J Investig Med; 1999 Sep; 47(8):343-57. PubMed ID: 10510587
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacogenomics: an in-house advantage?
    Borchardt PE
    Drug Discov Today; 2006 Jan; 11(1-2):1-3. PubMed ID: 16478684
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA pharmacogenomics guidance sends clear message to industry.
    Ratner M
    Nat Rev Drug Discov; 2005 May; 4(5):359. PubMed ID: 15902767
    [No Abstract]   [Full Text] [Related]  

  • 20. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
    Little S
    IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.